2008
DOI: 10.1016/j.vaccine.2008.07.004
|View full text |Cite
|
Sign up to set email alerts
|

Outer membrane vesicles as acellular vaccine against pertussis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

9
125
0
24

Year Published

2010
2010
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 147 publications
(158 citation statements)
references
References 36 publications
9
125
0
24
Order By: Relevance
“…We also evaluated the kinetics of B. pertussis clearance by counting the numbers of bacteria recovered from the lungs of mice simultaneously treated with LPS and B. pertussis at different times posttreatment (2,6,24, and 48 h). The results obtained again showed significant differences between the animals challenged with B. pertussis alone and the LPS-plus-B.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…We also evaluated the kinetics of B. pertussis clearance by counting the numbers of bacteria recovered from the lungs of mice simultaneously treated with LPS and B. pertussis at different times posttreatment (2,6,24, and 48 h). The results obtained again showed significant differences between the animals challenged with B. pertussis alone and the LPS-plus-B.…”
Section: Resultsmentioning
confidence: 99%
“…All of the mouse procedures were performed in accordance with Argentine regulations. Inoculums (10 7 CFU/40 l) were prepared, and the mice were inoculated intranasally as previously described (24). For bacterial counting, the mice were sacrificed by cervical dislocation, and their lungs were removed and homogenized in 1 ml of sterile phosphate-buffered saline (PBS).…”
Section: Methodsmentioning
confidence: 99%
“…OMVs from Salmonella enterica subsp. I serovar Typhimurium have been shown to stimulate both adaptive and innate im-mune responses, and OMVs from several species are immunogenic and protective in mouse models of infection (2,14,45,65). OMV-based intramuscularly delivered vaccines designed to protect against Neisseria meningitidis serogroup B infection have proved to be safe, immunogenic, and protective in human trials, as reviewed in reference 76. In 1977, it was found that subcutaneous immunization of mice with V. cholerae-derived vesicles protected their neonates from a lethal V. cholerae challenge (30).…”
mentioning
confidence: 99%
“…OMVs from a variety of bacteria have broad effects on animal immune responses (reviewed in reference 89). Native and modified OMVs have been implemented as vaccines against pathogens, such as Salmonella enterica serovar Typhimurium and Vibrio cholerae, in animal models (26,90,91) and have reached clinical usage against Neisseria meningitidis (92)(93)(94). Due to the size of OMVs, visualizing them in situ has generally required electron microscopy of fixed material, but improvements in superresolution techniques hold promise for tracking OMVs, their contents, and their interactions in living environments.…”
Section: Implications Of Omvs As Materials Goods and Missiles In Micromentioning
confidence: 99%